Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of RGT-264 Phosphate Tablets in Subjects With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of RGT-264 Phosphate Tablets in Subjects With Advanced Solid Tumors

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 10 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RGT-264 (Primary)
  • Indications Cholangiocarcinoma; Chondrosarcoma; Colon cancer; Kidney-neoplasms; Malignant melanoma; Nasopharyngeal cancer; Pancreatic cancer; Prostate cancer; Rectal cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Regor Therapeutics

Most Recent Events

  • 25 Oct 2024 Results (as data cut off date February 20, 2024, N= 11) assessing safety and tolerability were published at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics.
  • 31 Jul 2024 According to Clinicaltrial.gov record, this trial was terminated Due to the change in study plan and not due to safety reasons
  • 31 Jul 2024 Status changed from active, no longer recruiting to discontinued.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top